Navigation Links
Spherics, Inc. Assigns Assets to Joseph F. Finn, Jr., C.P.A.
Date:8/4/2008

WELLESLEY HILLS, Mass., Aug. 4 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn") announced today that the assets of Spherics, Inc. ("Spherics") had been assigned to him on July 28, 2008 for the benefit of creditors. An Assignment for the Benefit of Creditors is a common law procedure, wherein Finn will liquidate the assets, which consist primarily of pharmaceutical IP, by means of a sealed bid auction on October 10, 2008.

Persons interested in bidding must sign a Confidential Disclosure Agreement ("CDA") obtained from Finn's office. They will then receive a bid package and access to the Spherics electronic data room.

About Spherics

Spherics has built a strong intellectual property position around its drug delivery technologies and products. The Company has a broad range of issued US and international patents through exclusive licenses from Brown University. These patents cover polyanhydride-based bioadhesive polymers and PIN. In addition to these issued patents, Spherics has filed numerous applications covering compositions of matters of its proprietary polymers (SPHEROMERS), novel oral delivery systems (including BIOGIT, BIOROD and PIN), manufacturing methods, methods of use, formulations and product compositions.

About Joseph F. Finn, Jr., C.P.A.

Joseph F. Finn, Jr. is the founding partner of the firm Finn, Warnke & Gayton, Certified Public Accountants of Wellesley Hills, Massachusetts. He works primarily in the area of management consulting for distressed enterprises, bankruptcy accounting and related matters, such as assignee for the benefit of creditors and liquidating agent for a corporation. He has been involved in a number of loan workouts and bankruptcy cases for thirty-four (34) years. His most recent Assignment for the Benefit of Creditors in the Biotech field was ActivBiotics, Inc.


'/>"/>
SOURCE Spherics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Nastech Assigns Intellectual Property Related to the Development of RNA-Based Therapeutics to its Subsidiary, MDRNA, Inc.
2. BioEnergy International, LLC Acquires Assets of OmniGene Bioproducts, Inc.
3. Favrille Announces Resolution of Debt Obligations and Plans for Maximizing Assets
4. Veridex Announces Agreement to Acquire the Assets of Immunicon Corporation
5. VaxGen Sells Anthrax Vaccine Program and Related Assets and Technology to Emergent BioSolutions, Inc.
6. Derma Sciences Announces Agreement With MedAssets for MEDIHONEY(TM) Wound & Burn Dressings
7. bioMETRX, Inc. Initiates Integration of Personnel and Assets of Sequiam Corp.
8. Ortho Biotech Oncology Research & Development Unites Johnson & Johnson Biopharmaceutical Oncology R&D Assets
9. ActivBiotics Intellectual Property Assets, Including Drug Product Candidates, Sold for $3.5 Million
10. ActivBiotics Set to Sell Proprietary Assets, Including Drug Product Candidates, on March 14, 2008
11. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... (PRWEB) , ... February 09, 2016 , ... ... former Vice President for Public Policy for the National Organization for Rare Disorders ... advocacy groups to ensure their voices are heard throughout the drug regulatory review ...
(Date:2/9/2016)... , Feb. 9, 2016 This market ... the current and future prospects of the market in ... report include companies engaged in the manufacture of microbiology ... executive summary with a market snapshot providing the overall ... of this report. This section also provides the overall ...
(Date:2/9/2016)... -- Three-Year Initiative Supports Next Generation of Medical ... Life-Changing Camp Experiences ... the lives of children born with rare diseases, as well as ... is announcing a new initiative designed to positively affect the lives ... of rare disease care. --> To mark the company,s ...
(Date:2/9/2016)... 2016 DelveInsight,s, "Protein-Tyrosine ... provides in depth insights on the pipeline ... Protein-Tyrosine Phosphatase 1B (PTP1B) Inhibitors. The DelveInsight,s ... stages of development including Discovery, Pre-clinical, IND, ... Preregistration. Report covers the product clinical trials ...
Breaking Biology Technology:
(Date:1/22/2016)... , Jan. 22, 2016 ... the addition of the "Global Biometrics ... to their offering. --> ... the "Global Biometrics Market in Retail ... --> Research and Markets ...
(Date:1/20/2016)... , Jan. 20, 2016  Synaptics Incorporated ... human interface solutions, today announced sampling of S1423, ... for wearables and small screen applications including smartwatches, ... printers. Supporting round and rectangular shapes, as well ... excellent performance with moisture on screen, while wearing ...
(Date:1/13/2016)... 2016 http://www.researchandmarkets.com/research/7h6hnn/india_biometrics ... the  "India Biometrics Authentication & Identification ...  report to their offering.  ... the addition of the  "India Biometrics ... & Forecast (2015-2020)"  report to ...
Breaking Biology News(10 mins):